Biotechnology is one of our favorite sectors, because it offers investors the
opportunity to invest in companies where the fundamentals truly do matter. For
development-stage companies, it is rare to see their stocks rise and fall based
solely on macroeconomic headlines and rumors. And in today's volatile markets,
where it seems that everything is correlated and every stock is linked, it is
refreshing to see that biotechnology companies can still move to the beat of
their own drum. We would like to highlight one such company. Geron (GERN) is a Menlo Park, California, biotechnology company
specializing in oncology treatments. The next 12 months will be among the most
important in the company's history, and for risk-tolerant investors, now is the
time to buy shares
Check out the rest of the article it's long but very good. I've been saying the same thing for months.
This should take Geron to $2 if the market believes the article and in Geron.
Good luck in this rigged casino,
No comments:
Post a Comment